Analyzing Neuphoria Therapeutics (NASDAQ:NEUP) and Psyence Biomedical (NASDAQ:PBM)

Neuphoria Therapeutics (NASDAQ:NEUP) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Earnings & Valuation

This table compares Neuphoria Therapeutics and Psyence Biomedical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65 million	1.55	-$370,000.00	($11.06)	-0.41
Psyence Biomedical	N/A	N/A	$1.01 million	$25.34	0.14

Psyence Biomedical has lower revenue, but higher earnings than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neuphoria Therapeutics and Psyence Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Psyence Biomedical	N/A	N/A	N/A

Risk & Volatility

Neuphoria Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500.

Institutional & Insider Ownership

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Neuphoria Therapeutics and Psyence Biomedical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	2	1	0	2.00
Psyence Biomedical	1	0	0	0	1.00

Neuphoria Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 367.71%. Given Neuphoria Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than Psyence Biomedical.

Summary

Psyence Biomedical beats Neuphoria Therapeutics on 8 of the 12 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.